Company intelligence / Profile preview

photonamic GmbH & Co. KG

Pinneberg, Schleswig-Holstein, Germanyen.photonamic.de ↗

Ownership: Private
Employees: ~25
Development stage: Commercial

Overview

Successfully completed phase 3 study (MEN-301) investigating 5-ALA as an adjunct in meningioma patients undergoing fluorescence-guided surgery. Their product Gleolan®/Gliolan® is approved for fluorescence-guided resections of malignant gliomas. Aminolevulinic acid hydrochloride is in Phase II for Glioblastoma Multiforme with a 23% phase transition success rate for progressing to Phase III.[1][3]

Therapeutic areas: OncologyDermatology
Modalities: 5-aminolevulinic acid (5-ALA)
Industry: Biotech

Drug pipeline

1 asset

PDL-506

Unknown

Partnerships

Bayer HealthCare's Intendis (for PDT product outside the US)

Beyond the preview

Go deeper on photonamic GmbH & Co. KG.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on photonamic GmbH & Co. KG.

Explore the full profile